Immunic's Vidofludimus Calcium Shows Favorable Safety, Disability Signals in Additional Phase 2 Data
IMUX has more than doubled off its 52-week low of $5.062.
Summary
Immunic presented additional positive Phase 2 CALLIPER data for its drug candidate, vidofludimus calcium. The post-hoc analyses showed favorable safety, tolerability, and disability assessment signals, with consistent benefits over placebo for confirmed disability changes. Patient-reported outcomes also indicated no worsening in depression scores and higher perceived effectiveness. This news reinforces the positive efficacy and safety data previously announced on May 14th, further de-risking the drug's development pathway and strengthening its potential.
At the time of this announcement, IMUX was trading at $12.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $190.7M. The 52-week trading range was $5.06 to $15.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.